Overview

Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis

Status:
Not yet recruiting

Trial end date:
2027-10-30

Target enrollment:

Participant gender:

Summary

This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the Recommended Phase 2 Dose (RP2D). Once the RP2D is identified, 6 additional patients will be enrolled in the expansion cohort.

Phase:

Phase 1

Details

Lead Sponsor:

University of Utah

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a